HCP Inc Stock News

Upgrades According to UBS, the prior rating for Vipshop Holdings Ltd (NYSE:VIPS) was changed from Neutral to Buy. For the fourth quarter, Vipshop Holdings had an EPS of $0.53, compared to year-ago qua

Applied Materials (AMAT) delivered earnings and revenue surprises of 5.18% and 0.80%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Upgrades Guggenheim upgraded the previous rating for Immunovant Inc (NASDAQ:IMVT) from Neutral to Buy. In the third quarter, Immunovant showed an EPS of $0.49, compared to $0.36 from the year-ago quar

Best-of-breed cloud stocks to buy that can add rocket fuel to your long-term investing portfolio.

SAN FRANCISCO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today announced it will release financial result

SAN FRANCISCO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today announced it will release financial results

Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. Click here for a detailed analysis.

Some of the best times to invest in speculative names are when no one wants them. Check out these 10 stocks that possess high shareholder returns over the next decade.

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or i

The mean of analysts' price targets for HashiCorp, Inc. (HCP) points to a 67.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a

Philippe Laffont’s 13F portfolio value increased from $8.26B to $8.61B this quarter. Click here to read an update on the portfolio's trades for Q3 2022.

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share

The mean of analysts' price targets for HashiCorp, Inc. (HCP) points to a 56.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a

Needham analyst Alex Henderson maintained a Hold on HashiCorp, Inc (NASDAQ: HCP). Hashi demonstrated demand resilience against macro headwinds posting strong 52% Q3 revenue growth, beating consens

Analysts have provided the following ratings for HashiCorp (NASDAQ:HCP) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 3 0 0 Last 3